Paul J. Hastings is Director at Pacira Pharmaceuticals, Inc. (PCRX). They have made 26 open-market trades across 4 companies since 2013, most recently 2026-06-18.
CIK 0001309702
1 open-market purchase totalling $25K since 2013, against 25 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NKTX | 390,247 | $706K |
| PCRX | 12,724 | $463K |
| RLYP | 2,250 | $72K |
| OMED | 76,188 | $68K |
| Total | $1.3M |
Shares reported on the most recent Form 4, priced at the 2026-06-22 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NKTX | SELL | 2026-06-18 | 2026-06-22 | $2.71 | $5K | +12.0% | -15.8% | +0.2% |
| NKTX | SELL | 2026-01-15 | 2026-01-20 | $2.07 | $54K | +9.9% | +16.8% | +73.0% |
| NKTX | SELL | 2025-06-18 | 2025-06-20 | $1.79 | $3K | -2.2% | +7.9% | +11.8% |
| NKTX | SELL | 2025-01-15 | 2025-01-17 | $2.20 | $38K | -5.6% | -9.2% | -27.6% |
| NKTX | SELL | 2024-06-18 | 2024-06-20 | $5.60 | $10K | -1.5% | +21.2% | -1.3% |
| PCRX | SELL · 10b5-1 | 2024-06-13 | 2024-06-13 | $28.38 | $25K | -1.0% | -23.7% | -53.4% |
| NKTX | SELL | 2024-01-16 | 2024-01-18 | $8.74 | $170K | +10.0% | +23.0% | -6.3% |
| NKTX | SELL | 2023-06-20 | 2023-06-22 | $4.85 | $8K | -53.2% | -52.5% | -62.5% |
| PCRX | SELL | 2023-06-05 | 2023-06-07 | $38.34 | $22K | +9.4% | +1.4% | -7.0% |
| PCRX | SELL · 10b5-1 | 2023-05-15 | 2023-05-17 | $41.85 | $293K | -3.1% | +1.5% | -7.9% |
| NKTX | SELL | 2023-01-17 | 2023-01-18 | $5.49 | $20K | -1.4% | +5.6% | -7.2% |
| NKTX | SELL | 2022-09-28 | 2022-09-30 | $13.03 | $616K | -3.0% | -6.5% | -58.3% |
| NKTX | SELL | 2022-09-21 | 2022-09-22 | $13.01 | $159K | +16.8% | +2.4% | -52.2% |
| PCRX | SELL · 10b5-1 | 2022-07-11 | 2022-07-13 | $56.95 | $30K | +7.1% | +8.2% | +5.4% |
| NKTX | SELL | 2021-09-29 | 2021-10-01 | $27.19 | $456K | -28.0% | -35.9% | -41.8% |
| NKTX | SELL | 2021-06-21 | 2021-06-23 | $26.61 | $452K | +8.5% | +18.9% | +13.3% |
| PCRX | SELL · 10b5-1 | 2021-06-04 | 2021-06-08 | $62.19 | $39K | -1.9% | -7.4% | -7.2% |
| NKTX | SELL | 2021-03-30 | 2021-04-01 | $30.74 | $1.0M | +10.6% | -5.5% | -2.6% |
| PCRX | SELL | 2021-03-05 | 2021-03-09 | $65.88 | $198K | -0.8% | -3.0% | -12.6% |
| PCRX | SELL | 2020-06-04 | 2020-06-08 | $47.46 | $192K | -6.4% | +18.8% | +26.3% |
| PCRX | SELL · 10b5-1 | 2019-06-04 | 2019-06-06 | $42.66 | $33K | +3.1% | +1.9% | -13.9% |
| PCRX | SELL | 2018-06-04 | 2018-06-06 | $33.90 | $26K | -1.3% | -9.8% | +23.9% |
| OMED | SELL | 2017-10-10 | 2017-10-12 | $4.24 | $6K | -11.1% | +7.7% | -32.1% |
| PCRX | SELL | 2017-08-22 | 2017-08-24 | $36.15 | $38K | +0.3% | +1.2% | +20.1% |
| OMED | SELL | 2017-04-04 | 2017-04-05 | $9.06 | $117K | -55.9% | -58.7% | -59.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.